Min Li

Min Li

Auto-generated profile, based on publicly available information

Min Li

Department of Neurosurgery, Jiangning Hospital Affiliated with Nanjing Medical University, Nanjing, Jiangsu 211100, P.R. China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
GSGuan Sun
Guan Sun
LSLei Shi
Lei Shi
SYShushan Yan
Shushan Yan
ZWZhengqiang Wan
Zhengqiang Wan
NJNan Jiang
Nan Jiang
JGJun Guo
Jun Guo
Aim. To investigate the role and mechanism of miR-15b in the proliferation and apoptosis of glioma.Methods. The miR-15b mimics were transfected into human glioma cells to upregulate the miR-15b expression. Cyclin D1 was determined by both western blotting analysis and luciferase reporter assay. Methylthiazol tetrazolium (MTT) and flow cytometry were employed to detect the cell proliferation, cell cycle, and apoptosis.Results. Overexpression of miR-15b inhibits proliferation by arrested cell cycle progression and induces apoptosis, possibly by directly targeting Cyclin D1. Both luciferase assay and bioinformatics search revealed a putative target site of miR-15b binding to the 3′-UTR of Cyclin D1. Moreover, expression of miR-15b in glioma tissues was found to be inversely correlated with Cyclin D1 expression. Enforced Cyclin D1 could abrogate the miR-15b-mediated cell cycle arrest and apoptosis.Conclusions. Our findings identified that miR-15b may function as a glioma suppressor by targeting the Cyclin D1, which may provide a novel therapeutic strategy for treatment of glioma.

28 February 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
GSGuan Sun
Guan Sun
YCYing Cao
Ying Cao
YXYitian Xu
Yitian Xu
DHDe Huai
De Huai
PCPing Chen
Ping Chen
YDYuyu Dai
Yuyu Dai

14 April 2016 in Molecular Medicine Reports
Verified
Journal Article
Closed access
PDF file
GSGuan Sun
Guan Sun
SYShu-Shan Yan
Shu-Shan Yan
LSLei Shi
Lei Shi
ZWZheng-Qiang Wan
Zheng-Qiang Wan
NJNan Jiang
Nan Jiang
JGJun Guo
Jun Guo
Gliomas are the most common type of malignant brain tumor. Studies have identified that miR‑15b is negatively correlated with cripto-1 expression in glioma cells, and these molecules serve an important role in cancer development and progression. The current study was undertaken to further examine the association between these two molecules. Fluorescent quantitative PCR confirmed that miR‑15b expression was significantly downregulated in glioma tissue while cripto‑1 expression was significantly increased. Subsequent to transfection with miR‑15b mimics, cripto‑1 expression was significantly suppressed, and dual luciferase reporter assays further demonstrated that miR‑15b regulates cripto‑1 in a targeted manner. Furthermore, miR‑15b inhibited proliferation and invasion, and promoted apoptosis of glioma cells while downregulating the expression of MMP‑2 and MMP‑9. In contrast, cripto‑1 expression had the opposite effects. Co‑transfection with miR‑15b mimics and the cripto‑1 overexpression vector overcame the inhibitory action of miR‑15b on cripto‑1. Therefore, it is suggested that miR‑15b modulates cell growth and invasion through targeted regulation of cripto‑1 expression in glioma cells. This observation may provide novel targets for the prevention and treatment of gliomas.

1 April 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
GSGuan Sun
Guan Sun
JLJingmin Lu
Jingmin Lu
CZChuang Zhang
Chuang Zhang
RYRan You
Ran You
LSLei Shi
Lei Shi
JGJun Guo
Jun Guo
MiR-29b inhibits the growth of glioma via MYCN dependent way MiR-29b inhibits the growth of glioma via MYCN dependent way

3 January 2019 in NeuroMolecular Medicine
Verified
Journal Article
Closed access
PDF file
GSGuan Sun
Guan Sun
YCYing Cao
Ying Cao
XDXueliang Dai
Xueliang Dai
MLMin Li
Min Li
JGJun Guo
Jun Guo

18 December 2018 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
GSGuan Sun
Guan Sun
CZChuang Zhang
Chuang Zhang
HSHongmao Song
Hongmao Song
JGJun Guo
Jun Guo
MLMin Li
Min Li
YCYing Cao
Ying Cao
Glioblastoma is one of the most aggressive types of brain tumor. The median survival rate of patients with glioblastoma (World Health Organization grade IV) is <15 months. Therefore, there is an urgent requirement for the development of novel and efficient therapeutic agents against glioma. In previous studies, WZY‑321 (10‑hydroxy‑1‑methyl‑8,13b‑dihydro‑5H,7H‑benzo[e]benzofuro[2',3':3,4]pyrido[2,1‑b][1,3]oxazin‑5‑one), a novel evodiamine (Evo) analog, was reported to exhibit enhanced pharmacological properties and improved cytotoxicity against a number of human cancer cell lines compared with Evo. In the current study, the anti‑proliferative effect of WZY‑321 on SHG‑44 and SWO‑38 glioma cells was further studied, and its mechanism of action investigated. The results indicated that WZY‑321 inhibited the proliferation of SHG‑44 cells in a dose‑ and time‑dependent manner by enhancing cellular apoptosis and inducing cell cycle arrest at the G2‑M phase. Treatment of glioma cells with WZY‑321 concomitantly increased the expression levels of microtubule associated protein 1 light chain 3α and Beclin1, indicating enhanced autophagy. Overall, the results of the present study revealed the anti‑proliferative potential of WZY‑321 in glioma cells, thus providing a possible autophagy‑based therapeutic strategy for the treatment of glioblastoma.